Lantern Pharma Inc.

Lantern Pharma Inc.

LTRN · Nasdaq

Lantern Pharma Inc. (LTRN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Lantern Pharma Inc. in 2026. The next earnings report is expected on November 11, 2026.

Earnings calendar

Next earnings date

11 Nov 2026

In 84 days

EPS estimate

-0.38

Revenue estimate

0

Past earnings

14 Aug 2026
EPS actual
-0.57 (-50.0%)
estimate -0.38
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
15 May 2026
EPS actual
-0.30 (+16.7%)
estimate -0.36
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
30 Mar 2026
EPS actual
-0.36 (+21.7%)
estimate -0.46
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
13 Nov 2025
EPS actual
-0.39 (+17.0%)
estimate -0.47
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Lantern Pharma Inc. missed consensus estimates in its latest earnings report, with EPS of $-0.57 versus an estimate of $-0.38, while revenue of $0 met expectations. In the prior quarter EPS came in ahead of expectations and revenue also met estimates.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Panna Sharma
Employees
24
IPO date
11 Jun 2020
ISIN
US51654W1018
Website
lanternpharma.com

Frequently asked questions

When does Lantern Pharma Inc. (LTRN) next report earnings?

Lantern Pharma Inc. (LTRN) is scheduled to report earnings on November 11, 2026.

What was Lantern Pharma Inc.'s most recent earnings date?

Lantern Pharma Inc. (LTRN) last reported earnings on August 14, 2026.

Where is Lantern Pharma Inc. stock listed?

Lantern Pharma Inc. (LTRN) is listed on Nasdaq.